About Enhanc3D Genomics
Enhanc3D Genomics is a company based in Cambridge (United Kingdom) founded in 2020 by Peter Fraser, Mikhail Spivakov, and Stefan Schoenfelder.. Enhanc3D Genomics has raised $11.26 million across 1 funding round from investors including Parkwalk, BGF and Bioqube Ventures. The company has 12 employees as of January 31, 2022. Enhanc3D Genomics offers products and services including 3D Multi-Omics Platform and Cell Type-Specific Atlas.
- Headquarter Cambridge, United Kingdom
- Employees 12 as on 31 Jan, 2022
- Founders Peter Fraser, Mikhail Spivakov, Stefan Schoenfelder
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Enhanc3d Genomics Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$11.26 M (USD)
in 1 rounds
-
Latest Funding Round
$11.26 M (USD), Series A
Oct 20, 2022
-
Investors
Parkwalk
& 2 more
-
Employee Count
12
as on Jan 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enhanc3D Genomics
Enhanc3D Genomics offers a comprehensive portfolio of products and services, including 3D Multi-Omics Platform and Cell Type-Specific Atlas. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
This platform is employed to connect genetic variants to disease-driving genes across the genome for therapeutic discovery.
An atlas is used to facilitate the unlocking of decades’ worth of genomic data from numerous subjects for drug target validation.
Unlock access to complete
Unlock access to complete
Funding Insights of Enhanc3D Genomics
Enhanc3D Genomics has successfully raised a total of $11.26M through 1 strategic funding round. The most recent funding activity was a Series A round of $11.26 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $11.3M
-
First Round
First Round
(20 Oct 2022)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2022 | Amount | Series A - Enhanc3D Genomics | Valuation | Parkwalk , BGF |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enhanc3D Genomics
Enhanc3D Genomics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Parkwalk, BGF and Bioqube Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech companies are invested in by Parkwalk venture capital firm.
|
Founded Year | Domain | Location | |
|
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland
|
Founded Year | Domain | Location | |
|
Life sciences investments are managed by Bioqube Ventures in Europe and the US to advance therapeutic assets and technologies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enhanc3D Genomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enhanc3D Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enhanc3d Genomics Comparisons
Competitors of Enhanc3D Genomics
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Enhanc3D Genomics
When was Enhanc3D Genomics founded?
Enhanc3D Genomics was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Where is Enhanc3D Genomics located?
Enhanc3D Genomics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Who is the current CEO of Enhanc3D Genomics?
Debora Lucarelli is the current CEO of Enhanc3D Genomics.
Is Enhanc3D Genomics a funded company?
Enhanc3D Genomics is a funded company, having raised a total of $11.26M across 1 funding round to date. The company's 1st funding round was a Series A of $11.26M, raised on Oct 20, 2022.
How many employees does Enhanc3D Genomics have?
As of Jan 31, 2022, the latest employee count at Enhanc3D Genomics is 12.
What does Enhanc3D Genomics do?
Enhanc3D Genomics was founded in 2020 as a medical research lab based in Cambridge, United Kingdom. Operations center on genome sequencing studies to advance understanding in genomics. Core activities involve analyzing genetic data for research applications, with a team led by co-founders Peter Fraser, Mikhail Spivakov, and Stefan Schoenfelder, alongside CEO Debora Lucarelli. Focus remains on scientific contributions within the biotechnology sector.
What products or services does Enhanc3D Genomics offer?
Enhanc3D Genomics offers 3D Multi-Omics Platform and Cell Type-Specific Atlas.
Who are Enhanc3D Genomics's investors?
Enhanc3D Genomics has 3 investors. Key investors include Parkwalk, BGF, and Bioqube Ventures.